αHLA-G Exo-01NCT07219940
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 12 words
- Enrollment closed, study ongoing
- Site details revised
- Publications: details revised at 1 of 1 entry
- Minor Site contact updatedv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Nov 2025 to Dec 1, 2025
- Site details revised
- Minor Start date: Oct 2025 to Nov 2025v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of adverse event (AE)
Timeframe: From start until 3 weeks after the last dose of SOB100
Incidence of serious adverse event (SAE)
Timeframe: From start until 3 weeks after the last dose of SOB100
Incidence of treatment-emergent adverse event (TEAE)
Timeframe: From start until 3 weeks after the last dose of SOB100
Abnormalities in physical examination (PE)
Timeframe: From start until 3 weeks after the last dose of SOB100
Abnormalities in ECG
Timeframe: From start until 3 weeks after the last dose of SOB100
Arms and interventions
SOB100Experimental
Drugs: SOB100
Sites
1 site in 1 country
- Parexel International - Baltimore Early Phase Clinical UnitBaltimore, Maryland, United States